Date: 2015-03-11
Type of information: Licensing agreement
Compound: EB66® cell line to evaluate the production of additional vaccine candidates
Company: Valneva (France- Austria) Merial (France)
Therapeutic area: Veterinary medicine
Type agreement: licensing R&D
Action mechanism:
Disease:
Details: * On March 11, 2015, Valneva announced that it has signed a new research license agreement with Merial to develop veterinary vaccines using Valneva’s EB66® vaccine cell line platform. This agreement allows Merial to evaluate the production of additional vaccine candidates using the EB66® cell line platform, as a replacement for egg-based vaccine production. This new agreement strengthens the collaboration between the two companies, which have been partnering for about ten years, to generate EB66® cellbased veterinary vaccines. In May 2014, Merial received marketing approval by the European Medicines Agency (EMA) for its live EB66®-based Muscovy Duck Parvovirus Vaccine (MDPV), the first evermarketing authorization granted in Europe for a vaccine produced using the EB66®cell line.
Financial terms: Financial terms were not disclosed.
Latest news:
